Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Original Research

Artesunate antagonizes antiplasmodial activity of Vernonia amygdalina methanol leaf extract in murine model of malaria.

Chibueze Peter Ihekwereme,Paul Agafuchukwu,Earnest Oghenesuvwe Erhirhie.

Context: Malaria is a life-threatening disease in sub-Saharan Africa. Vernonia amygdalina (VAM), a popular Nigeria vegetable is commonly consumed by patients on antimalarial therapy, as a means of curbing resistance posed by Plasmodium species to conventional antimalarial drugs.
Objective: This study was designed to evaluate the effect of Artemisinin Combination Based Therapy (ACT), ART/Amodiaquine (A/A) on the antimalarial efficacy of VAM leaf extract.
Materials and Methods: Plasmodium berghi infected mice were randomized into six groups as follows; Group 1 (untreated control), group 2 (ART/VAM, 35.14/125 mg/kg), group 3 (ART, 35.14 mg/kg), group 4 (ART/A, 35.14/105 mg/kg), group 5 (VAM, 125 mg/kg) and group 6 (ART/VAM, 2.86/125 mg/kg). Administration lasted for three consecutive days and antiplasmodial activity was assessed using Rane’s curative test.
Result: Parasitemia clearance of 98.8 and 52.83% were recorded for VAM (125 mg/kg) and ART (35.14 mg/kg) respectively. However, lower parasitemia clearance of 97.05 and 80.49% were produced by the combinations of VAM/ART (125/2.86 mg/kg) and VAM/ART (125 mg/kg/35.14 mg/kg) respectively when compared to that of VAM, 125 mg/kg. A/A, (35.14/105 mg/kg) produced a parasite clearance of 89.69%.
Conclusion: ART produced dose dependent antagonism on the antimalarial efficacy of VAM. Combination of higher dose of ART and VAM should be discouraged, while the combination of low dose of ART and VAM could be encouraged for malaria patients.

Key words: Antagonism, Vernonia amygdalina, ACT, Plasmodium berghei, Artesunate, Interaction.

Full-text options

Full-text Article

American Journal of Preventive Medicine and Public Health


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.